RGPD5

Across TCGA pan-cancer cohorts, RGPD5 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated RGPD5 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RGPD5 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RGPD5 expression acts as an unfavorable survival marker, although some lineages such as UCS and PAAD show a favorable association.

STAD, ACC, and UCS are the cancer types where RGPD5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Quartile	II,III,IV	0.191	0.543	.002	57	view →
ACC	OS	Tertile	IV	0.145	0.730	.002	45	view →
UCS	OS	Tertile	IV	0.844	0.250	.016	20	view →
CESC	OS	Tertile	All	0.646	0.887	.007	16	view →
PAAD	DFS	Median	All	0.397	0.198	.001	15	view →
PRAD	DFS	Tertile	All	0.958	0.845	.010	14	view →
LUAD	DFS	Tertile	IV	0.616	0.976	.026	14	view →
MESO	DFS	Tertile	All	0.175	0.438	.026	12	view →
THCA	DFS	Tertile	III,IV	0.812	0.914	.022	12	view →
HNSC	DFS	Quartile	II,III,IV	0.183	0.636	.010	9	view →
BLCA	DFS	Quartile	IV	0.703	0.192	.038	7	view →
UVM	DFS	Median	All	0.264	0.561	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

RGPD5–STAD (DFS)

Open the STAD breakdown →